Please login to the form below

Not currently logged in
Email:
Password:

HCV

This page shows the latest HCV news and features for those working in and with pharma, biotech and healthcare.

Roche's O’Day swaps big pharma for big biotech

Roche's O’Day swaps big pharma for big biotech

The new CEO's main task will be to ensure the company's revenues can grow again, as its once-record-breaking hepatitis C (HCV) franchise continues to decline sharply: in ... O’Day joins Gilead as the big biotech company is on the hunt for new drugs to

Latest news

  • AbbVie sues NHS England over hep C procurement AbbVie sues NHS England over hep C procurement

    HCV drugs to be used in the programme, thought to be valued at hundreds of millions of pounds. ... treatment – as well as follow-up combinations such as Harvoni (sofosbuvir/ledipasvir) as well as Epclusa (sofosbuvir/velpatasvir) that was effective

  • Gilead wins European approval for triple hep C combination Vosevi Gilead wins European approval for triple hep C combination Vosevi

    This marks another win for the biopharma as Harvoni is the first DAA chronic HCV treatment to be granted an extension to treat adolescents in the European Union. ... the benefits of our other approved medicines for patients with chronic HCV infection

  • Merck & Co pulls out of hepatitis C R&D as market shrinks Merck & Co pulls out of hepatitis C R&D as market shrinks

    This turned out to be an over-confident prediction, with the HCV market already contracting as a result of pricing competition and a shrinking patient pool. ... The new decision comes after it already booked a $2.9bn impairment charge related to the HCV

  • Gilead makes $11.9bn play for CAR-T specialist Kite Gilead makes $11.9bn play for CAR-T specialist Kite

    Gilead's deal comes as it faces a sharp slowdown in sales of its HCV therapies - led by Harvoni (sofosbuvir and ledipasvir) and Sovaldi (sofosbuvir) - which has led investors to call ... makes it Gilead's largest takeover since it bought Pharmasset for

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or other drugs for HCV that inhibit a protein called NS5A". ... Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir

More from news
Approximately 8 fully matching, plus 112 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    HCV). As Gilead’s patent estate around these compounds is being challenged around the world, this appears to be a strategy of getting their response in first, and fending off both

  • Pharma deals in May 2015 Pharma deals in May 2015

    The agreement covers ACH 3102, ACH 3422 and sovaprevir. The intention is to trial a combination of ACH 3102 with a NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    virus (HCV) to help navigate the care system and make the most of new treatments. ... And obviously the NHS saves on downstream costs associated with HCV, such as liver disease and the prospect of liver transplants.

  • Communicating value Communicating value

    We are seeing instances, eg in HCV, where simple affordability, rather than cost effectiveness, is a major factor in spending decisions.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    42, 900. Idenix Pharmaceuticals/ Merck &Co. Company acquisition. Hepatitis C assets include IDX21437 (p1/2 nucleotide inhibitor) to combine with Merck HCV drugs. ... 75. Orion/ Bayer. Co-development, option to co-promote in Europe. OraQuick HCV rapid

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 8 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics